Context: Melasma is an acquired chronic disorder of hyperpigmentation. Tranexamic acid (TXA) has been shown to be effective in reducing the severity of melasma.
Aims: The aim of this study is to compare the efficacy of intralesional TXA with topical Kligman's regimen in the treatment of facial melasma and to assess their safety profile.
Settings And Design: A double arm open-labeled randomized controlled trial was conducted at a tertiary care center in western India.
Materials And Methods: Sixty-eight cases of facial melasma of either sex and age ≥ 18 years were randomized into two groups. Group A received intradermal injections of TXA 4 mg/mL, whereas group B received topical Kligman's therapy. Patients were evaluated at baseline, 4th, 8th, and 12th week semi-objectively using modified melasma area severity index (mMASI) score, physician's global assessment scale, and patient's global assessment scale.
Statistical Analysis: Data were analyzed using SPSS v16 software. Mann-Whitney -test, Friedman's analysis of variance test, and Pearson's χ test were used. -value less than 0.05 was considered as statistically significant.
Results: Fifty-nine patients completed the study. The decrease in mean mMASI score was statistically significant at 4th, 8th, and 12th week for both groups. On intergroup comparison, a statistically significant difference was observed between both the groups at 12th week ( < 0.01), with group B showing better response to therapy but no difference at baseline and at 4th and 8th week. Group A showed no significant side effects, whereas group B showed erythema, burning, and hypopigmentation in nine, six, and three patients, respectively.
Conclusion: Kligman's regimen remains the gold standard for melasma but with multiple serious adverse effects. Intralesional TXA is a safe and promising modality in the treatment of melasma. It can be used in non-responding cases and in those who develop side effects of Kligman's regimen.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364458 | PMC |
| http://dx.doi.org/10.4103/JCAS.JCAS_1_21 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Efficacy of Cysteamine Application for Melasma: A Meta-Analysis.
J Clin Med
December 2024
20skin Four Seasons Clinic, Taichung 408, Taiwan.
Melasma is a challenging, acquired hyperpigmentary disorder. The gold standard treatment is Kligman's formulation, which contains hydroquinone, tretinoin, and dexamethasone, but its long-term use is limited by the risk of exogenous ochronosis. Cysteamine, a tyrosinase inhibitor, reduces melanocyte activity and melanin production, showing strong depigmenting effects in patients resistant to Kligman's formulation.
View Article and Find Full Text PDFA Randomized Comparative Study of Intralesional Tranexemic Acid and Kligman's Regimen in Indian Patients with Melasma.
J Cutan Aesthet Surg
January 2022
Department of Pharmacology, Bundelkhand Medical College, Sagar, Madhya Pradesh, India.
Context: Melasma is an acquired chronic disorder of hyperpigmentation. Tranexamic acid (TXA) has been shown to be effective in reducing the severity of melasma.
Aims: The aim of this study is to compare the efficacy of intralesional TXA with topical Kligman's regimen in the treatment of facial melasma and to assess their safety profile.
A Pilot Study to Compare Therapeutic Efficacy and Safety of Combined Treatment of Skin Microneedling and Depigmenting Cream versus Depigmenting Cream Alone in Facial Melasma at Tertiary Care Center.
J Cutan Aesthet Surg
January 2021
Department of Dermatology, Venereology, and Leprosy, Surat Municipal Institute of Medical Education and Research (SMIMER), Surat, Gujarat, India.
Background: Melasma is a commonly acquired, chronic, and relapsing disorder that results in symmetrical, brownish facial pigmentation. It is more common in women than in men, which generally starts between 20 and 40 years of age, and it can lead to considerable embarrassment and distress. Managing melasma is a difficult challenge that requires long-term treatment with a number of topical agents.
View Article and Find Full Text PDFStudy of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma.
J Cosmet Dermatol
June 2020
JNMC, DMIMS DU, Wardha, India.
Background: Melasma is a pigmentary disorder affecting mainly face . Various treatment modalities available as topicals, superficial chemical peels and lasers but none till date gives promising results, until date quest for the best treatment modality is on.
Aim: To study the effect of oral and topical Tranexamic acid (TXA) and modified Kligman's regimen in treatment of melasma.
Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula.
J Cosmet Dermatol
February 2019
Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.
L-Cysteamine is a biological antioxidant produced during the coenzyme A metabolism cycle and is naturally present in all mammalian cells. The efficacy of topical cysteamine for the treatment of melasma has been recently shown in two double-blind, randomized, and placebo-controlled clinical trials. Herein, we report a 44-year-old patient with melasma resistant to Kligman's formula (Pigmanorm cream), who was successfully treated with topical cysteamine as a new depigmenting agent.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!